These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 21105885)

  • 1. A safety study of administration of parenteral testosterone undecanoate to elderly men over minimally 24 months.
    Haider A; Gooren LJ; Padungtod P; Saad F
    Andrologia; 2010 Dec; 42(6):349-55. PubMed ID: 21105885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate.
    Minnemann T; Schubert M; Hübler D; Gouni-Berthold I; Freude S; Schumann C; Oettel M; Ernst M; Mellinger U; Sommer F; Krone W; Jockenhövel F
    Aging Male; 2007 Sep; 10(3):155-8. PubMed ID: 17701659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study.
    von Eckardstein S; Nieschlag E
    J Androl; 2002; 23(3):419-25. PubMed ID: 12002444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
    Coward RM; Simhan J; Carson CC
    BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decline of plasma 5alpha-dihydrotestosterone (DHT) levels upon testosterone administration to elderly men with subnormal plasma testosterone and high DHT levels.
    Gooren LJ; Saad F; Haide A; Yassin A
    Andrologia; 2008 Oct; 40(5):298-302. PubMed ID: 18811920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido).
    Moisey R; Swinburne J; Orme S
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):642-7. PubMed ID: 18394021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
    Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
    J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY; Gu YQ; Wang XH; Cui YG; Bremner WJ
    J Androl; 1998; 19(6):761-8. PubMed ID: 9876028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A ten-year safety study of the oral androgen testosterone undecanoate.
    Gooren LJ
    J Androl; 1994; 15(3):212-5. PubMed ID: 7928661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndrome.
    Saad F; Gooren L; Haider A; Yassin A
    Andrologia; 2008 Feb; 40(1):44-8. PubMed ID: 18211301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate.
    Saad F; Gooren LJ; Haider A; Yassin A
    J Androl; 2008; 29(1):102-5. PubMed ID: 17916569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of 12 month oral testosterone on testosterone deficiency symptoms in symptomatic elderly males with low-normal gonadal status.
    Haren M; Chapman I; Coates P; Morley J; Wittert G
    Age Ageing; 2005 Mar; 34(2):125-30. PubMed ID: 15596419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
    Minnemann T; Schubert M; Freude S; Hübler D; Gouni-Berthold I; Schumann C; Christoph A; Oettel M; Ernst M; Mellinger U; Krone W; Jockenhövel F
    J Endocrinol Invest; 2008 Aug; 31(8):718-23. PubMed ID: 18852533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study.
    Morgentaler A; Dobs AS; Kaufman JM; Miner MM; Shabsigh R; Swerdloff RS; Wang C
    J Urol; 2008 Dec; 180(6):2307-13. PubMed ID: 18930255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with Andriol Testocaps--the first Austrian surveillance study on the treatment of late-onset hypogonadism.
    Jungwirth A; Plas E; Geurts P
    Aging Male; 2007 Dec; 10(4):183-7. PubMed ID: 18033627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints.
    Permpongkosol S; Tantirangsee N; Ratana-olarn K
    J Sex Med; 2010 Nov; 7(11):3765-74. PubMed ID: 20807330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and safety of long-acting testosterone undecanoate injections in hypogonadal men: an 84-week phase III clinical trial.
    Wang C; Harnett M; Dobs AS; Swerdloff RS
    J Androl; 2010; 31(5):457-65. PubMed ID: 20133964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate.
    Haider A; Gooren LJ; Padungtod P; Saad F
    Exp Clin Endocrinol Diabetes; 2010 Mar; 118(3):167-71. PubMed ID: 19472103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate.
    Yassin AA; Saad F
    Andrologia; 2007 Oct; 39(5):181-4. PubMed ID: 17714216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C-reactive protein levels and ageing male symptoms in hypogonadal men treated with testosterone supplementation.
    Giltay EJ; Haider A; Saad F; Gooren LJ
    Andrologia; 2008 Dec; 40(6):398-400. PubMed ID: 19032692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.